• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by PHAXIAM Therapeutics S.A..

    3/1/24 4:04:58 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHXM alert in real time by email
    25 1 d768090d25.htm 25 25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 25

     

     

    NOTIFICATION OF REMOVAL FROM LISTING AND/OR

    REGISTRATION UNDER SECTION 12(b) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Commission File Number 001-38281

     

     

    PHAXIAM Therapeutics S.A.

    The Nasdaq Capital Market

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

     

     

     

    France   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    60 Avenue Rockefeller

    Lyon, France

      69008
    (Address of Principal Executive Offices)   (Zip code)

    American Depositary Shares, each representing one ordinary share, nominal value €1.00 per share

    (Description of class of securities)

     

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

    ☐

    17 CFR 240.12d2-2(a)(1)

     

    ☐

    17 CFR 240.12d2-2(a)(2)

     

    ☐

    17 CFR 240.12d2-2(a)(3)

     

    ☐

    17 CFR 240.12d2-2(a)(4)

     

    ☐

    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

     

    ☒

    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

     

     


    Pursuant to the requirements of the Securities Exchange Act of 1934, PHAXIAM Therapeutics S.A. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

        PHAXIAM Therapeutics S.A.
    Date: March 1, 2024     By:  

    /s/ Eric Soyer

        Name:   Eric Soyer
        Title:   Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer
    Get the next $PHXM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHXM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PHXM
    SEC Filings

    View All

    SEC Form 15F-12B filed by PHAXIAM Therapeutics S.A..

    15F-12B - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

    3/11/24 8:31:57 AM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by PHAXIAM Therapeutics S.A..

    EFFECT - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

    3/6/24 12:15:07 AM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..

    S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

    3/4/24 4:28:57 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHXM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

    PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), hereafter "The Company" or PHAXIAM, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented th

    11/18/24 12:00:00 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

    Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company's voluntary delisting of American Depositary Shares ("ADSs") representing its ordinary shares from The Nasdaq Capital Market ("Nasdaq") has become effective. Each ADS represents one ordinary share of the Company. The Company will file a Form 15 with the Securities and Exchange Commission ("SEC") to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in respect of the ADSs and

    3/11/24 2:00:00 AM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

    PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq delisting will significantly reduce PHAXIAM's cash utilization and enable the Company to focus its financial resources on key development and value milestones Lyon (France) and Cambridge (MA, US), February 20, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced it has given formal notice to the Nasdaq Stock Market of the Company's intention to voluntary d

    2/20/24 4:05:00 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHXM
    Financials

    Live finance-specific insights

    View All

    PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

    Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024. Cash position as of December 31, 2023 As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million). With the implementation of additional cost-cutting measures, PHAXIAM Therapeutics estimates that its current cash position will enable the Company to finance its current programs and expected operating

    1/18/24 4:05:00 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

    Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indicationsEarly access program continues to gain momentum with the treatment of more than 90 patients suffering from severe and resistant infection prosthetic joint infections of the hip or knee (PJI) Cash and cash equivalents of €15.6 million ($16.5 million) as of September 30, 2023 Lyon (France) et Cambridge (MA, US), November 14, 2023, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant b

    11/14/23 4:05:00 PM ET
    $PHXM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care